News from sorrento therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 11, 2015, 06:00 ET
Sorrento Therapeutics, Inc.

Sorrento Therapeutics And Its Wholly-Owned Subsidiary, TNK Therapeutics, To Exclusively License CytoLumina's NanoVelcro Circulating Tumor Cell Profiling Assay

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it as well as its wholly-owned subsidiary TNK Therapeutics, Inc. have...

Aug 10, 2015, 06:00 ET
Sorrento Therapeutics, Inc.

Sorrento's TNK Therapeutics Subsidiary Acquires Multiple Clinical Stage CAR-T Immunotherapy Programs

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento) announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired...

Aug 03, 2015, 06:00 ET
Sorrento Therapeutics, Inc.

Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has entered into an exclusive licensing agreement to develop and...

Jul 17, 2015, 18:00 ET
Sorrento Therapeutics, Inc.

Sorrento Announces Departure of Mr. George Uy to become CEO of Start-up Company

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) a late-stage clinical oncology company developing new treatments for cancer and its associated...

Jul 09, 2015, 05:00 ET
167173LOGO

Sorrento and NantBioScience Form Joint Venture to Develop Moonshot Program Targeted Small Molecule Therapies against Cancer

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) and NantBioScience, Inc., a majority owned subsidiary of NantWorks, LLC, announced today...

Jun 29, 2015, 13:06 ET
Sorrento Therapeutics, Inc.

Sorrento Added to Russell 2000 Small Cap, Russell 3000 and Global Indexes

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today that it has been added to the Russell 2000® Small Cap, Russell...

Jun 24, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

ARK Animal Health, a Subsidiary of Sorrento Therapeutics, Announces Receipt of MUMS Drug Designation in Dogs

 ARK Animal Health, Inc., a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), , was granted a Minor Use/Minor...

May 26, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento to Present at the 2015 Jefferies Healthcare Conference and at Other Conferences

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a clinical stage oncology company developing new treatments for cancer and associated...

May 18, 2015, 22:41 ET

Sorrento crée TNK Therapeutics, une filiale spécialisée dans les immunothérapies cellulaires

- Le pipeline comprendra des CAR.TNKs™ en vente libre ainsi que des thérapies cellulaires et des immunothérapies...

May 18, 2015, 09:47 ET

Sorrento gründet Tochtergesellschaft TNK Therapeutics mit Fokus auf zelluläre Immuntherapien

- Pipeline wird CAR.TNKs™'von der Stange' sowie komplementäre zelluläre und Immuntherapien umfassen  Sorrento...

May 18, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Establishes TNK Therapeutics Subsidiary with Focus on Cellular Immunotherapies

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that it has formed a wholly-owned subsidiary, TNK (pronounced as "tank")...

May 18, 2015, 09:00 ET

Sorrento richt dochterbedrijf TNK Therapeutics op dat zich zal focussen op cellulaire immunotherapieën

- Pijplijn bevat CAR.TNKs™ 'van de plank' evenals aanvullende cellulaire en immunotherapieën  Sorrento Therapeutics, Inc....

May 15, 2015, 16:26 ET

NantWorks übernimmt Cynviloq™ für bis zu 1,3+ Milliarden USD

– Einstandszahlung in Höhe von 90+ Millionen USD und Meilensteinzahlungen von 1,2+ Milliarden USD – Sorrento behält Option...

May 15, 2015, 12:18 ET

NantWorks acquiert Cynviloq™ pour un montant supérieur à 1,3 milliard de dollars US

-- Un versement initial de plus de 90 millions d'USD et des versements échelonnés de plus de 1,2 milliard d'USD --Sorrento garde la...

May 15, 2015, 10:38 ET

NantWorks verwerft Cynviloq™ voor minimaal $ 1,3 miljard

--Betaling van minimaal $ 90 miljoen vooraf en minimaal $ 1,2 miljard aan mijlpaalbetalingen --Sorrento behoudt optie voor de gezamenlijke...

May 15, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

NantWorks Acquires Cynviloq™ For Up To $1.3+ Billion

Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), announced today that NantPharma, founded by Dr. Patrick Soon-Shiong and a member of the...

May 04, 2015, 10:44 ET

Sorrento gibt positive Ergebnisse für TRIBECA™ Zulassungsstudie bekannt

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) freut sich, positive Ergebnisse der vor kurzem analysierten pharmakokinetischen (PK) Daten aus seiner...

May 04, 2015, 09:46 ET

Sorrento annonce des résultats positifs pour son étude d'homologation TRIBECA™

Sorrento Therapeutics, Inc. (NASDAQ : SRNE) est heureuse d'annoncer des résultats positifs des données de pharmacocinétique...

May 04, 2015, 09:31 ET

Sorrento kondigt een positief resultaat aan van het TRIBECA™-registratieonderzoek

Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is verheugd met de bekendmaking van het positieve resultaat van de onlangs geanalyseerde...

May 04, 2015, 09:00 ET
Sorrento Therapeutics, Inc.

Sorrento Announces Positive TRIBECA™ Registrational Study Results

 Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is pleased to announce positive results from recently analyzed pharmacokinetic (PK) data from its...